Status:
UNKNOWN
Evaluation of the Treatment Approach ROBIN
Lead Sponsor:
University of Zurich
Conditions:
Clinical High Risk for Psychosis
Eligibility:
All Genders
14-18 years
Phase:
NA
Brief Summary
The prevention of schizophrenia and other psychotic disorders has led researchers to focus on early identification of individuals at Clinical High Risk (CHR) for psychosis and to treat the at-risk sym...
Eligibility Criteria
Inclusion
- 1\) At least two self-experienced and self-reported cognitive basic symptoms as assessed by the children-youth version of the Schizophrenia Proneness Interview Child and Youth Version (SPI-CY)
- and/or 2) at least one attenuated psychotic symptom for psychosis assessed by the Structured Interview for Prodromal Syndromes (SIPS)
Exclusion
- a diagnosis of a psychotic disorder
- current substance or alcohol dependence
- insufficient German or English language ability
- low intellectual abilities with IQ \<75
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03829527
Start Date
September 1 2017
End Date
September 30 2022
Last Update
February 4 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Zurich, Department of Child and Adolescent Psychiatry and Psychotherapy
Zurich, Switzerland, 8032